Últimas noticias sobre Moolec Science (NASDAQ:MLEC) Bolsa

Moolec Science

Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.

Moolec Science SA

Value stocks are having a rough go in 2024, at least compared to broader stock indexes.
The benchmark S&amp;P Value Index is up 10.46% on a year-to-date basis. That's well below the S&amp;P 500, which has generated 23.8% returns over the same time period. The index is also well below the year-to-date performance of the S&amp;P Growth Index, which stands at 35.11% as of December 20.
Yet as the calendar flips to 2025, value stocks seem to be in a decent position.
Here&#8217;s three reasons why value stocks may be a good bet for 2025.
"Inflation is moderating, and the economy seems to be steadying," says Jason Hishmeh, co-founder at Varyence, a technology firm that works with startup companies to grow their business. "That's great news for sectors like manufacturing, financials, and energy, which tend to perform well in this environment. Companies with strong fundamentals—low price-to-earnings ratios and steady earnings growth—look particularly attractive."
Other market experts say Main Street investors need to get a good grip on what value stocks really represent.
"Value stocks are a group of underappreciated and ignored stocks that are worth more than their fundamentals would suggest," says Stephen Callahan, trading behavior analyst at Firstrade. "This is a market driven by momentum. As a value investor, valuations are never a reason to own something. Fundamentals are the reason why you own something. We need to match those two things up." What's more, not all cheap stocks are value stocks.
"Some stocks are cheap for quantifiable reasons, such as poor earnings," Callahan says. "Value stocks are good companies at low prices. They are financially stable, have high-profit margins, low debt-to-income ratio, strong earnings, and while not mandatory, a good sign is that they pay dividends."
Value stocks have several trends pointing upward heading into a new year. Market experts point to these largest 2025 impactors.
<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-holiday-24/?t=be16bespmirebz36&amp;utm_source=WebRD-1219">[65% Off Benzinga Edge – Sale Ends December 31!]</a>
Back in business under Trump. President-elect Donald Trump said he'd prioritize a business-friendly agenda in his campaign stump speeches, which would be good news for value stocks.
"Trump spoke frequently about reducing the government deficit, lowering energy costs through increased domestic drilling, and implementing potentially looser regulations," says Ronen Cojocaru, CEO at San Francisco-based 8081.io, a fintech company that simplifies and automates digital asset trading. "Additionally, the prospect of corporate-friendly tax reforms could enhance profitability, making value stocks more attractive to investors."
Key expectations coming from the Trump camp include reduced regulations in sectors such as energy, financials, crypto, and industrials, which could lower compliance costs and increase profitability.
"Additionally, corporate-friendly tax reforms may enhance earnings, while a focus on domestic production and energy independence could create new opportunities for growth in the energy and manufacturing sectors," Cojocaru says. "But we should all look carefully at how Trump administration tariffs will take place, which can play a significant role in that space."
Large-cap value stocks to shine. In early December, BofA analysts projected the U.S. gross domestic product would rise by 2.4%, well ahead of other analyst projections that landed in the 2.0% range. Economists say that any GDP above 2% is good news for well-run, long-established companies that turn a profit.
So-called "GDP-sensitive" companies should benefit from a growing U.S. economy. &#8220;We see more opportunities in stocks than the index,&#8221; notes BofA head of U.S. equity and quantitative strategy Savita Subramanian in a recent research note, which pegged the S&amp;P 500 at a 6,666 target price for 2025. &#8220;In particular, we like companies with healthy cash return prospects and a tether to the US economy: large-cap value stocks.&#8221;
Cojocaru says large-cap value stocks are well-positioned to perform strongly in 2025, especially if the trends highlighted by BofA analysts continue to shape the market.
"Companies in this sector demonstrated remarkable resilience in 2024, navigating a high-inflation environment by adopting strict cost controls, improving operational efficiency, and managing capital strategically," he notes. "These actions now yield significant benefits as inflation moderates and interest rates show signs of stabilizing or potentially declining."
An upward trending economy. With analysts calling for a healthy US economy, a strong labor market, moderating inflation, and the resulting potential for further interest rate cuts, value stocks should rise accordingly.
"The economy is looking pretty solid right now, with strong jobs, inflation starting to settle, and maybe even some interest rate cuts on the horizon,"&nbsp; says Nick Scibilia, CEO of Orbit, a social media platform geared toward younger investors.&nbsp;
That scenario represents "awesome news" for value stocks, Scibilia notes. "People are spending more, businesses are booming, and that means more cash for those established companies," he says. "Plus, if interest rates drop, those steady dividend-paying value stocks will look even better."
Watch out for risks. Even with a generally rosy outlook on the sector, value investors should know various possible risks.
"Firstly, if inflation persists and interest rates continue to increase, value stocks could underperform," Scibilia says. "Secondly, a recession is still possible, and value stocks are not immune to economic downturns. Lastly, geopolitical uncertainty and global events could disrupt market conditions and negatively impact value stocks."
Still, Scibilia sees several sectors looking pretty hot right now.
"Energy has been a bit wild lately with prices bouncing around, but things are looking good long term," he notes. "Also, when the economy is humming, industrials are in high demand. Think infrastructure, manufacturing, transportation &#8211; they&#8217;re all key players in keeping things moving."
Additionally, robust economic fundamentals should help stocks across the board next year.
&#8220;A stronger economy is good for all solid companies, even ones that aren't considered value stocks right now," says Paul Gabrail, founder and host of the Everything Money YouTube channel. "The goal is to increase revenue and profit; over time, the stock price and value of the company will converge.&#8221;
Find the market's fastest-moving stocks and access real-time alerts, expert trade setups, and insider stock picks with Benzinga Edge. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-holiday-24/?t=be16bespmirebz36&amp;utm_source=WebRD-1219">Click here to take advantage of our End-of-Year Sale which ends December 31!</a>
Image via Pixabay

Opinion

Trading Ideas

3 Reasons to Buy Value Stocks Before January 1

WIIM

RDDT

Reddit shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and a $210 price target.

Financial giants have made a conspicuous bearish move on Super Micro Computer. Our analysis of options history for Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) revealed 28 unusual trades.
Delving into the details, we found 39% of traders were bullish, while 46% showed bearish tendencies. Out of all the trades we spotted, 15 were puts, with a value of $865,180, and 13 were calls, valued at $493,490.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.0 to $90.0 for Super Micro Computer over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Super Micro Computer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Super Micro Computer's significant trades, within a strike price range of $7.0 to $90.0, over the past month.
<h3>Super Micro Computer 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723033_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$19.05</td>
<td>$18.9</td>
<td>$18.98</td>
<td>$50.00</td>
<td>$189.8K</td>
<td>3.9K</td>
<td align="right">150</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/24/25</td>
<td>$19.5</td>
<td>$18.7</td>
<td>$19.4</td>
<td>$50.00</td>
<td>$96.9K</td>
<td>38</td>
<td align="right">50</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$58.7</td>
<td>$57.9</td>
<td>$58.6</td>
<td>$90.00</td>
<td>$93.7K</td>
<td>686</td>
<td align="right">16</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$6.55</td>
<td>$6.65</td>
<td>$33.00</td>
<td>$66.5K</td>
<td>5.9K</td>
<td align="right">203</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.35</td>
<td>$6.1</td>
<td>$6.27</td>
<td>$32.00</td>
<td>$62.7K</td>
<td>890</td>
<td align="right">252</td>
</tr>
</tbody>
</table>

<h3>About Super Micro Computer</h3>
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data center, Big Data, high-performance computing, and "Internet of Things" embedded markets. Its solutions include server, storage, blade and workstations to full racks, networking devices, and server management software. The firm follows a modular architectural approach, which provides flexibility to deliver customized solutions. The Company operates in one operating segment that develops and provides high-performance server solutions based upon an innovative, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
Following our analysis of the options activities associated with Super Micro Computer, we pivot to a closer look at the company's own performance.
<h3>Where Is Super Micro Computer Standing Right Now?</h3>
<ul>
<li>With a volume of 31,110,491, the price of SMCI is up 3.09% at $32.2. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 11 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Super Micro Computer with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

SMCI

What the Options Market Tells Us About Super Micro Computer

Deep-pocketed investors have adopted a bearish approach towards Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in QCOM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 19 extraordinary options activities for Qualcomm. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 26% leaning bullish and 42% bearish. Among these notable options, 7 are puts, totaling $664,115, and 12 are calls, amounting to $1,189,524.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $140.0 to $180.0 for Qualcomm during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Qualcomm's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Qualcomm's substantial trades, within a strike price spectrum from $140.0 to $180.0 over the preceding 30 days.
<h3>Qualcomm Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723028_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$23.75</td>
<td>$23.3</td>
<td>$23.75</td>
<td>$140.00</td>
<td>$474.6K</td>
<td>142</td>
<td align="right">200</td>
</tr>
<tr>
<td>QCOM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.29</td>
<td>$2.13</td>
<td>$2.14</td>
<td>$180.00</td>
<td>$242.0K</td>
<td>2.8K</td>
<td align="right">20</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$15.05</td>
<td>$14.5</td>
<td>$14.5</td>
<td>$165.00</td>
<td>$211.7K</td>
<td>1.2K</td>
<td align="right">26</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.9</td>
<td>$5.7</td>
<td>$5.75</td>
<td>$150.00</td>
<td>$129.3K</td>
<td>8.2K</td>
<td align="right">390</td>
</tr>
<tr>
<td>QCOM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$18.15</td>
<td>$17.85</td>
<td>$18.01</td>
<td>$170.00</td>
<td>$90.0K</td>
<td>8.6K</td>
<td align="right">346</td>
</tr>
</tbody>
</table>

<h3>About Qualcomm</h3>
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.
<h3>Current Position of Qualcomm</h3>
<ul>
<li>With a volume of 4,767,794, the price of QCOM is up 1.8% at $153.1. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 40 days.</li>
</ul>
<h3>What The Experts Say On Qualcomm</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $180.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Melius Research has revised its rating downward to Hold, adjusting the price target to $180. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Qualcomm with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

QCOM

Spotlight on Qualcomm: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 35 extraordinary options activities for Advanced Micro Devices. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 65% leaning bullish and 14% bearish. Among these notable options, 16 are puts, totaling $1,369,153, and 19 are calls, amounting to $2,358,178.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $230.0 for Advanced Micro Devices over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Advanced Micro Devices's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Advanced Micro Devices's whale trades within a strike price range from $85.0 to $230.0 in the last 30 days. 
<h3>Advanced Micro Devices Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734723023_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$37.25</td>
<td>$37.15</td>
<td>$37.15</td>
<td>$100.00</td>
<td>$1.4M</td>
<td>8.1K</td>
<td>3.1K</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$71.75</td>
<td>$71.6</td>
<td>$71.6</td>
<td>$190.00</td>
<td>$400.9K</td>
<td>1.7K</td>
<td>56</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$21.75</td>
<td>$21.55</td>
<td>$21.61</td>
<td>$140.00</td>
<td>$252.8K</td>
<td>3.7K</td>
<td>1</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$17.55</td>
<td>$17.5</td>
<td>$17.55</td>
<td>$130.00</td>
<td>$93.0K</td>
<td>15.2K</td>
<td>302</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$22.15</td>
<td>$21.8</td>
<td>$22.0</td>
<td>$150.00</td>
<td>$88.0K</td>
<td>3.5K</td>
<td>44</td>
</tr>
</tbody>
</table>

<h3>About Advanced Micro Devices</h3>
Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.
After a thorough review of the options trading surrounding Advanced Micro Devices, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Advanced Micro Devices</h3>
<ul>
<li>Trading volume stands at 29,364,681, with AMD's price up by 0.98%, positioned at $120.04.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 39 days.</li>
</ul>
<h3>Professional Analyst Ratings for Advanced Micro Devices</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $164.33333333333334.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Advanced Micro Devices, maintaining a target price of $158. 
&#x2A; An analyst from B of A Securities has revised its rating downward to Neutral, adjusting the price target to $155. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Advanced Micro Devices, targeting a price of $180. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Advanced Micro Devices, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on AMD Options

QUBT

Quantum Computing shares are trading higher. The company announced a $2.9 million share offering of 8.96 million shares for resale by the selling stockholder.

Billionaire Stanley Druckenmiller, a former confidant of George Soros and the founder of Duquesne Capital, built his career off making <a href="https://www.benzinga.com/general/24/03/37598371/stanley-druckenmillers-secret-sauce-the-two-stocks-dominating-a-quarter-of-his-three-billion-dollar">large, measured bets</a>. His latest large wager has paid off.
The famed investor has steadily increased his stake in Natera Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a clinical genetic testing company, since the third quarter of 2022, according to quarterly 13F filings. Druckenmiller owned 414,955 shares in 2022&#8217;s third quarter, 893,030 shares in 2023 and 3,566,850 shares in 2024.
Druckenmiller&#8217;s position now exceeds $575 million, nearly 3% of the Austin, Texas-based company&#8217;s market capitalization and 15% of Duquesne Capital&#8217;s portfolio.
Since Duquesne Capital revealed its stake in a 13F filing, its stock has traded up 268%. Meanwhile, the healthcare industry as a whole, as measured by the iShares US Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>), has risen a touch over 16%. Thus, Druckenmiller&#8217;s gamble has outperformed its sector by over 250%.
Also Read: <a href="https://www.benzinga.com/markets/equities/24/12/42624528/government-shutdown-threat-stocks-wobble-holiday-travel-and-paychecks-could-face-delays-what-you-need-to-know">Government Shutdown Threat: Holiday Travel, Paychecks Could Face Delays If No Deal Reached</a>
Natera specializes in genetic testing and diagnostics to improve healthcare outcomes. The company develops and markets tests that analyze DNA to provide insights into hereditary conditions, reproductive health, organ transplant health, and oncology. 
Natera's flagship products include non-invasive prenatal tests (NIPTs) like Panorama, which screens for chromosomal abnormalities in a fetus, and Horizon, a carrier screening test for hereditary conditions.
In recent years, Natera has expanded its focus to oncology and organ transplant monitoring. In oncology, the company's Signatera test detects minimal residual disease (MRD) in cancer patients, helping to guide treatment decisions and monitor for recurrence with precision.
In the transplant space, the Prospera test assesses organ health by measuring donor-derived cell-free DNA, providing early indications of transplant rejection.
The company has beaten earnings and revenue expectations over the past four quarters. Revenue has increased from $625 million in 2021 to $1.5 billion over the past twelve months, while margins have also expanded. The company has posted a positive operating cash flow since March.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42623343/exclusive-weight-loss-market-experts-scoop-up-novo-nordisk-stock-after-worst-drop-since-2002-following-drug-trial-miss">EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Health Care

Hedge Funds

General

iShares Trust Dow Jones US Healthcare Sector Index Fund

NTRA

Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%

News

Rumors

Watching Nano Nuclear Energy; Shares See A Pop To The Upside As Traders Circulate Popular Stock Trader X Account Suggesting They Have Taken A Long Position On The Stock

Macro Economic Events

Politics

Economics

U.S. House Speaker Johnson Says We Have A Unified Agreement Among Republicans To Move Forward On Spending Deal; We Will Not Have A Government Shutdown

BlackBerry Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) stock surged upwards on Friday. The company reported <a target="_blank" href="https://www.benzinga.com/news/earnings/24/12/42606549/blackberry-beats-q3-earnings-estimates-but-soft-guidance-keeps-shares-in-check" rel="noreferrer noopener">third-quarter results</a> after the market closed on Thursday.
BlackBerry reported quarterly revenue of $143.00 million, missing the analyst consensus estimate of $161.49 million. The adjusted EPS was $0.02, beating analyst&nbsp;estimates.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42529245/trump-and-netflix-boss-sarandos-set-for-high-stakes-mar-a-lago-meeting" rel="noreferrer noopener">Trump and Netflix Boss Sarandos Set for High-Stakes Mar-a-Lago Meeting</a>
BlackBerry expects fourth-quarter revenue of $126.00 million &#8211; $135.00 million, versus estimates of $150.08 million. It expects adjusted EPS of $(0.01) &#8211; $0.01. Analysts rerated the stock after the quarterly print.
RBC Capital analyst Paul Treiber reiterated BlackBerry with a Sector Perform and a <a target="_blank" href="https://www.benzinga.com/quote/BB/analyst-ratings" rel="noreferrer noopener">$3.25&nbsp;price target</a>.
BlackBerry&#8217;s third quarter marks its first quarter of financials without Cylance. The quarter exceeded Treiber&#8217;s estimates, though fourth-quarter guidance was short of his expectations.
Excluding Cylance (discontinued operations), third-quarter revenue was $143 million (-7% year-on-year), above Treiber&#8217;s estimated $128 million. All three revenue lines exceeded the analyst&#8217;s expectations: IoT ($62 million versus RBC and consensus at $58 million and $59 million), Secure Communications ($74 million versus RBC at $66 million), and Licensing ($7 million versus RBC and consensus at $4 million). Due to higher revenue, adjusted EBITDA was $35 million, above RBC at $13 million.
The fourth-quarter revenue guidance short of RBC. It calls for $126 million &#8211; $135 million in revenue, below RBC&#8217;s estimate of $138 million. The shortfall stems from Secure Communications ($62 million &#8211; $66 million versus RBC at $71 million). IoT guidance for $60 million &#8211; $65 million bracketed RBC estimate ($64 million). The mid-point of adjusted EBITDA guidance for $10 million &#8211; $20 million missed the RBC estimate of $19 million.
BlackBerry is now profitable and operating cash flow positive. However, Treiber noted that the valuation will likely remain discounted below that of peers pending improved IoT growth (fourth-quarter guidance calls for IoT revenue to be down 5% year-on-year at the mid-point).
BlackBerry is trading at a discounted valuation of 3.0 times NTM Enterprise Value/Sales.
Treiber noted that BlackBerry&#8217;s valuation will likely remain discounted, pending strengthening IoT growth and realizing improved profitability. The price target includes the $120 million cash proceeds from the sale of Cylance and values Secure Communications at 6.0 times calendar 2025 Enterprise Value/EBITDA (unchanged) and the IoT business at 6.1 times calendar 2025 Enterprise Value/ Sales (unchanged).
Price Action: BB stock is up 23.5% at $3.679 at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42536593/verizon-teams-up-with-nvidia-to-power-ai-apps-over-private-5g-networks" target="_blank" rel="noreferrer noopener">Verizon Teams Up With Nvidia To Power AI Apps Over Private 5G Networks</a></li>
</ul>
Image via Shutterstock.

Analyst Color

Price Target

Reiteration

Analyst Ratings

BlackBerry Growth Hinge On IoT, Secure Communications Despite Valuation Concerns: Analyst

Oppenheimer initiated coverage on Rhythm Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a developer of treatment for rare obesity disorders.
The pharmaceutical industry&#8217;s focus on weight management is drawing strong investor interest, with Rhythm Pharmaceuticals standing out for targeting rare obesity disorders that standard treatments often fail to address.
The company is steadily growing its business through the global rollout of Imcivree, a drug designed for several<a href="https://www.benzinga.com/pressreleases/24/12/g42284805/rhythm-pharmaceuticals-announces-imcivree-setmelanotide-receives-expanded-marketing-authorization-" target="_blank" rel="noreferrer noopener"> genetic obesity conditions</a>.
Also Read: <a href="https://www.benzinga.com//node/42613036">Novo Nordisk&#8217;s Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges</a>
Revenue from global sales of IMCIVREE was $33.3 million for the third quarter of 2024, an increase of 14% on a sequential basis, primarily driven by sales for BBS.
In the third quarter of 2024, revenue of $23.3 million, or 70% of product revenue, was <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41757397/rhythm-pharmaceuticals-reports-third-quarter-2024-financial-results-and-business-update" rel="noreferrer noopener">generated in the U.S.</a>
Oppenheimer is optimistic about its progress in treating hypothalamic obesity, an acquired condition with high development potential, as Phase 3 trial results are expected in the first half of 2025.
Oppenheimer initiated coverage on Rhythm Pharmaceuticals with an Outperform rating and a <a target="_blank" href="https://www.benzinga.com/quote/RYTM/analyst-ratings" rel="noreferrer noopener">price target of $76</a>.
Rhythm&#8217;s expertise in MC4 biology positions it for long-term success as Imcivree&#8217;s approved uses expand, new pipeline drugs with improved efficacy and convenience advance, and the company enhances its efforts to identify patients with genetic obesity.
The analyst anticipates significant growth opportunities in 2025 and beyond as Rhythm taps into a multi-billion-dollar total addressable market.
The analyst highlights that severe obesity caused by MC4R pathway defects doesn&#8217;t respond well to popular GLP-1 drugs like Novo Nordisk A/S&#8217;&nbsp;&nbsp;Wegovy or Eli Lilly And Co&#8217;s Zepbound, noting the experts and studies.
The MC4R drug market has little competition. Palatin Technologies Inc. markets Vyleesi (bremelanotide) for sexual disorders and is testing it with Zepbound for general obesity, with results expected in early 2025. Palatin is also developing oral MC4R drugs.
Price Action: RYTM stock is up 1.71% at $56.43 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623020/why-innovative-industrial-stock-is-falling-over-20-today" target="_blank" rel="noreferrer noopener">Innovative Industrial Properties Hit By Cannabis Company PharmaCann&#8217;s Rent Default, Stock Plunges</a></li>
</ul>
Photo via Shutterstock.

Biotech

Initiation

RYTM

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

LTRY

Lottery.Com shares are trading higher after the company announced it received a Nasdaq compliance determination letter.

ENVX

Enovix shares are trading higher after the company announced it shipped its first EX-2M samples to customers manufactured in its Malaysian Fab 2 plant.

Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) sell-off on Friday saw prices dip below $93,000, but Bitwise CIO Matt Hougan argues that the <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42614273/bitcoin-crashes-10-ethereum-xrp-down-18-dogecoin-craters-28-what-is-going-on">current pullback is a &#8220;hiccup&#8221;</a> rather than a trend reversal.
Hougan sees strong underlying factors including <a href="https://www.benzinga.com/news/events/24/11/41992186/could-new-legislation-finally-bring-clarity-to-us-crypto-rules-industry-expert-weighs-in">regulatory tailwinds</a>, <a href="https://www.benzinga.com/24/12/42516240/the-doors-have-been-blown-off-how-bitcoin-etfs-are-reshaping-investment-strategies">institutional adoption</a> and <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41847581/el-salvadors-bitcoin-bet-is-paying-off-heres-how-much-the-country-is-up">Bitcoin purchases by governments</a> as structurally bullish factors for Bitcoin.
<h2 class="wp-block-heading">Crypto&#8217;s Turbulent Friday Trading Session</h2>
The cryptocurrency market experienced a volatile session Friday, triggered by the <a href="https://www.benzinga.com/24/12/42564443/santa-came-early-with-rate-cut-but-federal-reserve-brings-coal-next-year-experts-weigh-in-on-rate-cut-feds-2025-projections">Federal Reserve&#8217;s decision</a> to lower its anticipated rate cuts for the coming year.
Bitcoin plummeted from a high of $108,135 to below $92,805, before rebounding slightly, currently trading around $96,950, down 1.2% on the day.
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) also traded down by 1% to $3,430.
This sharp decline mirrored a <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42615908/feds-preferred-inflation-gauge-falls-more-than-expected-markets-breathe-sigh-of-relief">broader pullback in risk assets</a>, with the S&amp;P 500 dropping 3% and the Russell 2000 Small Cap Index falling 4.4% following the Fed announcement.
The Fed&#8217;s move, while expected in terms of a <a href="https://www.benzinga.com/24/12/42610958/expecting-up-to-four-fed-rate-cuts-in-2025-says-this-analyst-despite-hawkish-powell-saying-it-was-close-on-the-decision-to-cut-or-not-heres-why">25 basis point rate cut</a>, surprised markets with its <a href="https://www.benzinga.com/24/12/42564443/santa-came-early-with-rate-cut-but-federal-reserve-brings-coal-next-year-experts-weigh-in-on-rate-cut-feds-2025-projections">reduced forecast</a> for future cuts. It is now projecting only two in 2025, down from four.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42623985/rattled-hawk-tuah-girl-haliey-welch-resurfaces-after-meme-coin-scandal-i-take-this-situation-extremely-seriously">Rattled &#8216;Hawk Tuah Girl&#8217; Haliey Welch Resurfaces After Meme Coin Scandal: &#8216;I Take This Situation Extremely Seriously&#8217;</a>
<h2 class="wp-block-heading">The Fed Matters For Crypto — But Other Factors Matter More</h2>
Potentially higher interest rates traditionally pressure risk assets, and this announcement initiated an initial sell-off across the board, Matt Hougan noted in a social media thread earlier in the day.
However, he emphasized that leverage within the crypto market acted as a significant catalyst for the deeper-than-expected decline. 
Hougan maintains that the broader bull market trend remains intact — $1.38 billion of liquidated positions in 24 hours notwithstanding.
He claims the Fed is less impactful to the sector than in previous years, and the industry has gained significant internal momentum due to several fundamental shifts.
He points to several key factors supporting the bullish thesis: 
<ul>
<li>An imminent pro-crypto regulatory shift in Washington, see Trump&#8217;s appointment of a &#8216;<a href="https://www.benzinga.com/24/12/42356067/venture-capitalist-david-sacks-appointed-as-white-house-ai-crypto-czar-by-trump">crypto czar</a>.&#8217;</li>
<li>Increasing institutional involvement and ETF flows, such as <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42393396/record-week-bitcoin-etfs-net-25-billion-in-inflows-ethereum-etfs-took-in-12-billion">record-breaking spot ETF flows</a>.</li>
<li>Bitcoin acquisitions by governments and corporations — even <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42601193/senator-lummis-introduces-strategic-bitcoin-reserve-proposal">a strategic Bitcoin reserve</a> may be on the table.</li>
<li>Major technological advancements in the programmable blockchain sector (<a href="https://www.benzinga.com/24/12/42443799/merging-systems-tokenization-and-the-path-to-financial-change">tokenization anyone</a>?).</li>
</ul>
In a series of <a href="https://x.com/Matt_Hougan/status/1869627742561649100">tweets</a>, Hougan also highlighted that Bitcoin&#8217;s 10-day exponential moving average (approximately $102,000) remains above its 20-day exponential moving average (around $99,000), which is a traditional bullish indicator for him. 
This technical measure has historically been a reliable gauge of market trends and suggests the medium term trend for Bitcoin, despite the volatility, is still positive.
<h2 class="wp-block-heading">What Technical Indicators Are Saying</h2>
According to James Toledano, Chief Operating Officer at Unity Wallet, &#8220;Profit taking is definitely at play here, with Bitcoin trading volume rising 24% in the last day and Bitcoin ETF outflows hitting a record $672M in 1 day.&#8221; 
This shows recent price volatility is not solely attributable to external influences, but internal to the market as well.
&#8220;Many people who invested earlier in the year will have doubled their money and those who invested years ago, made more than they ever dreamt possible,&#8221; he told Benzinga.
Toledano also noted that whilst Bitcoin trading volume is skewed towards selling, altcoins have been subject to significant trading activity.
Ethereum trading volume is up 45% over 24 hours, with 70% of that buying activity.
XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), currently up 1% on the day and recovering from a 20% drop earlier in the day, is seeing a similar volume pattern.
BNB (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/bnb/usd">BNB</a>) is also up 1.3% at $670.
However, Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is down 1% and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) down about 5% , hile SUI (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SUI</a>) is up 7% at press time.
While reduced liquidity in the upcoming holiday period could lead to increased volatility, Toledano added, the absence of major institutional activity may stabilize prices. 
He also pointed out that, based on historic trends, there is no clear pattern at this time of the year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42617815/are-microstrategys-bitcoin-purchases-on-hold-in-january">Are MicroStrategy&#8217;s Bitcoin Purchases On Hold In January?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BNB

$BTC

$DOGE

$ETH

$SHIB

$SUI

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Whipsaw, But These 4 Key Factors Make It A 'Hiccup,' Not A Downturn

Legal

U.S. Jury Is Deadlocked On One Of Questions In Arm's Lawsuit Against Qualcomm, But Is Still Deliberating

Lottery.com Receives Compliance Determination Letter From Nasdaq; Shares Spike Higher

Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration&nbsp;(FDA) has approved an expanded indication for IMCIVREE&#xAE; (setmelanotide) to include children as young as 2 years old. IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long-term in patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency.
BBS and POMC, PCSK1 and LEPR deficiencies are rare melanocortin-4 receptor (MC4R) pathway diseases with hallmark characteristics that include hyperphagia, or pathological, insatiable hunger and impaired satiety accompanied by persistent and abnormal food-seeking behaviors, and early-onset obesity. IMCIVREE is the first and only precision medicine to target impairment of the hypothalamic MC4R pathway, a root cause of hyperphagia and obesity due to BBS and POMC, PCSK1 and LEPR deficiencies in adults and children as young as 2 years old in the United States, as well as Europe.

hythm Pharmaceuticals Secures FDA Approval For Expanded Use Of IMCIVREE To Treat Obesity In Children As Young As 2 With Bardet-Biedl Syndrome Or MC4R Pathway Deficiencies, Targeting Rare Neuroendocrine Diseases

IIPR

Innovative Industrial Properties shares are trading lower after the company reported a default by Pharmacann on its obligations to pay rent for six of its eleven leases in December.

PODD

Insulet shares are trading higher amid strength in diabetes-related stocks following weight loss data from Novo Nordisk.

During the last three months, 15 analysts shared their evaluations of Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">13</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $18.53, a high estimate of $20.00, and a low estimate of $16.50. Observing a 5.76% increase, the current average has risen from the previous average price target of $17.52. 
<img src="https://www.benzinga.com/files/images/story/2024/1734721259_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Invesco by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.50</td>
<td>$17.50</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$17.50</td>
<td>$16.50</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$17.50</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$17.50</td>
<td>$17.25</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$16.50</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Invesco. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Invesco compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Invesco's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Invesco's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/IVZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Invesco analyst ratings.</a>
<h2>Unveiling the Story Behind Invesco</h2>
Invesco provides investment-management services to retail (68% of managed assets) and institutional (32%) clients. At the end of October 2024, the firm had $1.792 trillion in assets under management spread among its equity (58% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (10%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's us retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 29% of its AUM sourced from Europe, Africa, and the Middle East (14%) and Asia (15%).
<h3>Invesco: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Invesco's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 5.09%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Invesco's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 3.63%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.52%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Invesco's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.2%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.69, Invesco adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Invesco Stock: A Deep Dive Into Analyst Perspectives (15 Ratings)

Maxim Group analyst Anthony Vendetti reiterated a Buy rating on Moolec Science (MLEC – Research Report) yesterday and set a price target of $6.00. ...

Buy Rating Affirmed: Moolec Science Poised for Growth with Strategic Partnerships and Strong Market Potential

Moolec Science (MLEC) has released an update. Moolec Science and Bunge have forged a partnership to develop new safflower varieties, enhancing prod...

Moolec Science and Bunge's Strategic Safflower Venture

Warning: MLEC is at high risk of performing badly

Moolec Science (MLEC) has released an update. Moolec Science SA, a leader in molecular farming for food ingredients, has been notified by Nasdaq of...

Moolec Science Faces Nasdaq Compliance Challenge

Moolec Science gets non-compliance notice from Nasdaq

Earnings week ahead: Nike, Carnival, Constellation Brands, and more

Moolec Science GAAP EPS of -$0.07, revenue of $1.52M

Moolec Science (MLEC) Q4 2024 Earnings Call Transcript

Moolec Science (MLEC) has released an update. Moolec Science has achieved a groundbreaking milestone by securing USDA approval for its genetically ...

Moolec Science Gains Historic USDA Approval

Moolec Science ( ($MLEC) ) has shared an announcement. Moolec Science SA has announced its upcoming Annual General Meeting (AGM) and Extraordinary ...

Moolec Science Announces AGM and EGM with Key Resolutions

AIXI

ANGO

APOG

CALM

LEVI

LFCR

MESA

MLEC

MLECW

NEOV

PAYX

POCI

STBX

TRAK

UNFI

VLGEA

WKEY

Press Releases

Thinking about buying stock in Moolec Science, Bakkt Holdings, EHang Holdings, Arcadium Lithium, or Assertio Holdings?

Earnings

Moolec Science to Host Second Quarter Fiscal Year 2024 Business Update Conference Call

Moolec Science to Host Third Quarter Fiscal Year 2024 Business Update Conference Call

Moolec Signs an Offtake Agreement With Major Global CPG Company to Hit the US Market in 2025

Moolec Received NASDAQ Bid Price Letter

Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call

Moolec Science Presents Fiscal Year 2024 Annual Business Update

Moolec Has Received USDA Approval for the First Genetically Modified Pea in History

ASRT

BKKT

LTHM

Forafric Global

Branchout Food

Barfresh Food Group

Bridgford Foods Corporation - Common Stock

Bridgford Foods

Borealis Foods Inc. - Class A Common Shares

Borealis Foods

Beyond Meat

Australian Oilseeds Holdings Limited - Ordinary Shares

Australian Oilseeds Hldgs

DDC Enterprise Limited Class A Ordinary Shares

DDC Enterprise

Farmer Bros

CIMG

Coffee Holding Co

Laird Superfood

Lifeway Foods

Mama`s Creations

Oriental Rise Holdings Limited - Ordinary Shares

Oriental Rise Holdings

Oatly Group AB - American Depositary Shares

Oatly Group

TDH Hldgs

Planet Green Holdings

The Real Good Food Company, Inc. - Class A Common Stock

Real Good Food Co

Rocky Mountain Chocolate Factory, Inc. - Common Stock

Rocky Mountain Chocolate

Sow Good

Steakholder Foods Ltd. - American Depositary Shares

Steakholder Foods

Top Wealth Group Holding Limited - Ordinary Shares

Top Wealth Group

Wing Yip Food Holdings Group Limited - American Depositary Shares

Wing Yip Food Holdings

Maxim Group

Comments

Moolec Science

Noticias

Últimas noticias sobre Moolec Science (NASDAQ:MLEC) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL